January 30, 2025Open Access

LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials

Key Points

Key points are not available for this paper at this time.

Abstract

LLDAS and DORIS remission, which are associated with favourable outcomes such as reduced damage and mortality in patients with SLE, are attainable and sustainable treatment targets with long-term anifrolumab treatment.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Morand et al. (Thu,) studied this question.

synapsesocial.com/papers/69d9548f5e5bcb4e3b835902 https://doi.org/https://doi.org/10.1016/j.ard.2025.01.016

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Targeting DORIS Remission and LLDAS in SLE: A Review2023 · 25 citations
2Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study2024 · 30 citations
3Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression2024 · 36 citations
4Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus2023 · 68 citations
5Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort2022 · 56 citations

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper